Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN loss |
| Therapy | GSK2636771 + Paclitaxel |
| Indication/Tumor Type | stomach cancer |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN loss | stomach cancer | no benefit | GSK2636771 + Paclitaxel | Phase II | Actionable | In a Phase II trial (K-Umbrella), GSK2636771 and Taxol (paclitaxel) combination therapy did not significantly improve median progression-free survival (2.8 vs 4.0 months) or median overall survival (7.0 vs 8.7 months) in patients with advanced ERBB2 (HER2)-negative gastric cancer harboring PTEN loss compared to standard of care in the control group (PMID: 37883723; NCT02951091). | 37883723 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37883723) | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study. | Full reference... |